Top Cited Articles

We are delighted to share the 2019 impact factor for the International Journal of Gynecological Cancer of 2.095 (Journal Citation Reports, Clarivate Analytics), which ranked 41/82 in the Obstetrics and Gynecology category and 195/244 in the Oncology category.

The quality and impact of our journals are dependent on many different measures. We’ve provided here some of those metrics for International Journal of Gynecological Cancer, to reflect the latest 2020 data, that remain important to our authors. We’ve also listed our top most cited articles from each of the last two years, free to read.


COVID-19 Global Pandemic: Options for Management of Gynecologic Cancers
APRIL 2020 10.1136/ijgc-2020-001419

SUCCOR study: an international European cohort observational study comparing minimally invasive surgery versus open abdominal radical hysterectomy in patients with stage IB1 cervical cancer
SEPTEMBER 2020 10.1136/ijgc-2020-001506

Primary cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy (HIPEC) for FIGO stage III epithelial ovarian cancer: OVHIPEC-2, a phase III randomized clinical trial
JUNE 2020 10.1136/ijgc-2020-001231

Laparoscopic radical hysterectomy: a European Society of Gynaecological Oncology (ESGO) statement
JANUARY 2020 10.1136/ijgc-2019-000775

A randomized phase III trial of platinum chemotherapy plus paclitaxel with bevacizumab and atezolizumab versus platinum chemotherapy plus paclitaxel and bevacizumab in metastatic (stage IVB), persistent, or recurrent carcinoma of the cervix: the BEATcc study (ENGOT-Cx10/GEICO 68-C/JGOG1084/GOG-3030)
JANUARY 2020 10.1136/ijgc-2019-000880

European Society of Gynaecological Oncology quality indicators for surgical treatment of cervical cancer
JANUARY 2020 10.1136/ijgc-2019-000878

Randomized trial of primary debulking surgery versus neoadjuvant chemotherapy for advanced epithelial ovarian cancer (SCORPION-NCT01461850)
NOVEMBER 2020 10.1136/ijgc-2020-001640

ERAS protocols in gynecologic oncology during COVID-19 pandemic
JUNE 2020 10.1136/ijgc-2020-001439

Anti-PD-L1 (atezolizumab) as an immune primer and concurrently with extended-field chemoradiotherapy for node-positive locally advanced cervical cancer
MAY 2020 10.1136/ijgc-2019-001012

Discrepancy in calculated and measured glomerular filtration rates in patients treated with PARP inhibitors
JANUARY 2020 10.1136/ijgc-2019-000714


Guidelines for perioperative care in gynecologic/oncology: Enhanced Recovery After Surgery (ERAS) Society recommendations—2019 update
MARCH 2019 10.1136/ijgc-2019-000356

Laparoscopic radical hysterectomy with transvaginal closure of vaginal cuff – a multicenter analysis
JUNE 2019 10.1136/ijgc-2019-000388

SENTICOL III: an international validation study of sentinel node biopsy in early cervical cancer. A GINECO, ENGOT, GCIG and multicenter study
MAY 2019 10.1136/ijgc-2019-000332

A prospective multicenter trial on sentinel lymph node biopsy in patients with early-stage cervical cancer (SENTIX)
JANUARY 2019 10.1136/ijgc-2018-000010

Impact of micrometastasis or isolated tumor cells on recurrence and survival in patients with early cervical cancer: SENTICOL Trial
MARCH 2019 10.1136/ijgc-2018-000089

The first Japanese nationwide multicenter study of BRCA mutation testing in ovarian cancer: CHARacterizing the cross-sectionaL approach to Ovarian cancer geneTic TEsting of BRCA (CHARLOTTE)
JULY 2019 10.1136/ijgc-2019-000384

ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease
MAY 2019 10.1136/ijgc-2019-000308

TRUST: Trial of Radical Upfront Surgical Therapy in advanced ovarian cancer (ENGOT ov33/AGO-OVAR OP7)
OCTOBER 2019 10.1136/ijgc-2019-000682

Clinical application of the sentinel lymph node technique in early ovarian cancer: a pilot study
FEBRUARY 2019 10.1136/ijgc-2018-000049

Association of metformin use with ovarian cancer incidence and prognosis: a systematic review and meta-analysis
JANUARY 2019 10.1136/ijgc-2018-000060

Journal Metrics:

Days to first decision: 16
Days from acceptance to publication: 29

2 year Impact Factor (JCR): 2.095
SciMago Journal Rank (SJR): 1.011
Eigenfactor: 0.01217
Citescore: 3.8

2019 total Content accesses: 310,000
Altmetric score: 2,688